Trial Profile

Prospective, Open-label, Comparative, Multicenter Study of Voriconazole Compared to Itraconazole for the Primary Prophylaxis of Invasive Fungal Infections (IFI) in Subjects with Allogeneic Hematopoietic Stem Cell Transplants (HSCT)

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 06 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Voriconazole (Primary) ; Voriconazole (Primary) ; Itraconazole; Itraconazole
Indications Mycoses
Focus Adverse reactions; Therapeutic Use
Acronyms IMPROVIT
Sponsors Pfizer

07 Jun 2011 New trial record
25 May 2011 Economic results for the first 100 days presented at the International Meeting of the International Society for Pharmacoeconomics and Outcomes Research.
10 May 2011 Economic results after the first 100 days presented at the 21st European Congress of Clinical Microbiology and Infectious Diseases and the 27th International Congress of Chemotherapy.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com